CDAKQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CDAKQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Codiak BioSciences's operating cash flow per share for the three months ended in Sep. 2022 was $-0.40. Codiak BioSciences's operating cash flow per share for the trailing twelve months (TTM) ended in Sep. 2022 was $-2.94.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Codiak BioSciences's Operating Cash Flow per Share or its related term are showing as below:
The historical data trend for Codiak BioSciences's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Codiak BioSciences Annual Data | |||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | |||||
Operating Cash Flow per Share | -2.33 | -0.13 | -10.01 | -3.40 |
Codiak BioSciences Quarterly Data | |||||||||||||||
Dec18 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
Operating Cash Flow per Share | Get a 7-Day Free Trial | -0.69 | -0.96 | -0.93 | -0.65 | -0.40 |
For the Biotechnology subindustry, Codiak BioSciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Codiak BioSciences's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Codiak BioSciences's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.
Codiak BioSciences's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2021 is calculated as
Operating Cash Flow per Share (A: Dec. 2021 ) | = | Cash Flow from Operations (A: Dec. 2021 ) | / | Shares Outstanding (Diluted Average) (A: Dec. 2021 ) |
= | -74.144 | / | 21.795 | |
= | -3.40 |
Codiak BioSciences's Operating Cash Flow per Share for the quarter that ended in Dec. 2021 is calculated as
Operating Cash Flow per Share (Q: Sep. 2022 ) | = | Cash Flow from Operations (Q: Sep. 2022 ) | / | Shares Outstanding (Diluted Average) (Q: Sep. 2022 ) |
= | -10.11 | / | 25.160 | |
= | -0.40 |
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.94
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Codiak BioSciences's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Yalonda Howze | officer: See Remarks | C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140 |
Sriram Sathyanarayanan | officer: Chief Scientific Officer | C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140 |
Nicole Barna | officer: See Remarks | C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140 |
Douglas E Williams | director, officer: President & CEO | C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799 |
Linda Bain | officer: Chief Financial Officer | C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Konstantin Konstantinov | officer: See Remarks | C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139 |
Arch Venture Fund Viii Overage, L.p. | 10 percent owner | C/O ARCH VENTURE PARTNERS VIII, LLC, 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
David J Mauro | officer: Chief Medical Officer | 36 TERRELL DRIVE, WASHINGTON CROSS PA 18977 |
Arundathy N. Pandite | director | 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703 |
Benny Sorensen | officer: See Remarks | C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140 |
Anne-virginie Eggimann | director | C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140 |
Jennifer J. Wheler | officer: Chief Medical Officer | C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140 |
Briggs Morrison | director | C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451 |
Alaska Permanent Fund Corp | 10 percent owner | 801 WEST 10TH STREET, SUITE 302, JUNEAU AK 99801 |
Flagship Ventures Fund V, L.p. | 10 percent owner | ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-15-2022
By PurpleRose PurpleRose • 07-15-2022
By PRNewswire PRNewswire • 08-18-2022
By GuruFocusNews GuruFocusNews • 06-29-2022
By GuruFocusNews GuruFocusNews • 06-16-2022
By GuruFocusNews GuruFocusNews • 07-05-2022
By GuruFocusNews GuruFocusNews • 05-26-2022
By GuruFocusNews GuruFocusNews • 05-27-2022
By Ds*** Ds*** • 08-30-2022
By PurpleRose PurpleRose • 07-15-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.